Medische Oncologie Nummer 2, pp. 26-28
jun 2001, jaargang 4
Medische Oncologie Nr. 2, pp. 26-28
jun 2001, jr. 4
BOM

Vinorelbine bij mammacarcinoom

Lees online

De conclusie is wanneer de huidige gegevens uit gerandomiseerd onderzoek worden getoetst aan de Paskwilcriteria, vinorelbine geen meerwaarde heeft boven de eerste- of tweedelijns standaardbehandeling.

Referenties

  1. Barni S, Ardizzola A, Bernardo G, et al. Vinorelbine as single agent in pretreated patients with advanced breast cancer. Tumori 1994, 80: 280-282.
  2. Blajman C, Balbiani L, Block J, et al. A prospective, Randomized Phase II Trial Comparing Combination Chemotherapy with Cyclophosphamide, Doxorubicin, and 5- Fluorouracil with Vinorelbine plus Doxorubicin in the Treatment of Advanced Breast Carcinoma. Cancer 1999, 85:1091-1097.
  3. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994, 5: 423-426.
  4. Fumoleau P, Delgado FM, Delozier T, et al. Phase II Trial of Weekly Intravenous Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy. J Clin Oncol 1993, 11: 1245-1252.
  5. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994, 5: 854-857.
  6. Gasparini G, Caffo O, Barni S, et al. Vinorelbine Is an Active Antiproliferative Agent in Pretreated Advaced Breast Cancer Patients: A Phase II Study. J Clin Oncol 1994, 12:2094-2101.
  7. Jones S, Winer E, Vogel C, et al. Randomized Comparison of Vinorelbine and Melphalan in Anthracycline-Refractory Advanced Breast Cancer. J Clin Oncol 1995, 13: 2567-2574.
  8. Norris B, Pritchard KI, James K, et al. Phase II Comparative Study of Vinorelbine Combined with Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000, 18: 2385-2394.
  9. Romero A, Rabinovich MG, Vallejo CT, et al. Vinorelbine as First-Line Chemotherapy for Metastatic Breast Carcinoma. J Clin Oncol 1994,12: 336-341.
  10. Terenzani M, Demicheli R, Brambilla C, et al. Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996, 39: 285-291.
  11. Twelves CJ, Dobbs NA, Curnow A, et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994, 70: 990-993.
  12. Vogel C, O’Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999, 10: 397-402.
BOM

Vinorelbine bij mammacarcinoom

Lees online

De conclusie is wanneer de huidige gegevens uit gerandomiseerd onderzoek worden getoetst aan de Paskwilcriteria, vinorelbine geen meerwaarde heeft boven de eerste- of tweedelijns standaardbehandeling.

Referenties

  1. Barni S, Ardizzola A, Bernardo G, et al. Vinorelbine as single agent in pretreated patients with advanced breast cancer. Tumori 1994, 80: 280-282.
  2. Blajman C, Balbiani L, Block J, et al. A prospective, Randomized Phase II Trial Comparing Combination Chemotherapy with Cyclophosphamide, Doxorubicin, and 5- Fluorouracil with Vinorelbine plus Doxorubicin in the Treatment of Advanced Breast Carcinoma. Cancer 1999, 85:1091-1097.
  3. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994, 5: 423-426.
  4. Fumoleau P, Delgado FM, Delozier T, et al. Phase II Trial of Weekly Intravenous Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy. J Clin Oncol 1993, 11: 1245-1252.
  5. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994, 5: 854-857.
  6. Gasparini G, Caffo O, Barni S, et al. Vinorelbine Is an Active Antiproliferative Agent in Pretreated Advaced Breast Cancer Patients: A Phase II Study. J Clin Oncol 1994, 12:2094-2101.
  7. Jones S, Winer E, Vogel C, et al. Randomized Comparison of Vinorelbine and Melphalan in Anthracycline-Refractory Advanced Breast Cancer. J Clin Oncol 1995, 13: 2567-2574.
  8. Norris B, Pritchard KI, James K, et al. Phase II Comparative Study of Vinorelbine Combined with Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000, 18: 2385-2394.
  9. Romero A, Rabinovich MG, Vallejo CT, et al. Vinorelbine as First-Line Chemotherapy for Metastatic Breast Carcinoma. J Clin Oncol 1994,12: 336-341.
  10. Terenzani M, Demicheli R, Brambilla C, et al. Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996, 39: 285-291.
  11. Twelves CJ, Dobbs NA, Curnow A, et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994, 70: 990-993.
  12. Vogel C, O’Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999, 10: 397-402.
Over dit artikel
Auteur
NVMO-commissie BOM
Printdatum
14 juni 2001
E-pubdatum
17 juni 2001
ISSN print
1388-2295
ISSN online
2405-4763


Over dit artikel
Auteur
NVMO-commissie BOM
Printdatum
14 juni 2001
E-pubdatum
17 juni 2001
ISSN print
1388-2295
ISSN online
2405-4763